Bacterial infections in cirrhosis

被引:0
|
作者
Gregory J. Botwin
Timothy R. Morgan
机构
[1] VA Long Beach Healthcare System,Gastroenterology Services, VA Long Beach Healthcare Group
[2] University of California,11 (GI)
来源
关键词
Infection; Cirrhosis; Antibiotics; Multidrug-resistant bacteria; Survival; Sepsis;
D O I
暂无
中图分类号
学科分类号
摘要
Bacterial infections occur in 25–35 % of cirrhotics admitted to hospital. Health-care associated and hospital acquired (nosocomial) infections are the most common epidemiology, with community acquired infections less common (15–30 %). Spontaneous bacterial peritonitis and urinary infections are the most common sites, with spontaneous bacteremia, pneumonia, cellulitis and other sites being less common. The risk of infection is increased among subjects with more severe liver disease and an infection in the past 6 months. Bacteria are isolated from approximately half of patients with a clinical diagnosis of infection. Gram-negative enterobacteriaceae are the most common organisms among community acquired infections; Gram-positive cocci are the most common organisms isolated among subjects with nosocomial infections. Up to 30 % of hospital associated infections are with multidrug resistant bacteria. Consequently, empiric antibiotic therapy that is recommended for community acquired infections is often inadequate for nosocomial infections. Infections worsen liver function. In-hospital and 1-year mortality of cirrhotics with infections is significantly higher than among cirrhotics without infection. In-hospital complications of infections, such as severe sepsis and septic shock, and mortality, are increased among subjects with multidrug-resistant infections as compared with cirrhotics with susceptible bacteria. Short-term antibiotic prophylaxis of cirrhotics with upper gastrointestinal bleeding and long-term antibiotic prophylaxis of selected cirrhotics with spontaneous bacterial peritonitis reduces infections and improves survival. Albumin administration to cirrhotics with SBP and evidence of advanced liver disease improves survival. The benefit of albumin administration to cirrhotics with infections other than SBP is under investigation.
引用
收藏
页码:467 / 474
页数:7
相关论文
共 50 条
  • [21] Bacterial Infections in Cirrhosis as a Cause or Consequence of Decompensation?
    Piano, Salvatore
    Angeli, Paolo
    CLINICS IN LIVER DISEASE, 2021, 25 (02) : 357 - 372
  • [22] Changing flora of bacterial infections in patients with cirrhosis
    Runyon, Bruce A.
    LIVER INTERNATIONAL, 2010, 30 (09) : 1245 - 1246
  • [23] New determinants of prognosis in bacterial infections in cirrhosis
    Acevedo, Juan
    Fernandez, Javier
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (23) : 7252 - 7259
  • [24] Immunosuppression and Increased Risk of Bacterial Infections in Cirrhosis
    Moreau, Richard
    Arroyo, Vicente
    INFECTIOUS MICROBES & DISEASES, 2021, 3 (03): : 115 - 116
  • [25] Bacterial infections, sepsis, and multiorgan failure in cirrhosis
    Tandon, Puneeta
    Garcia-Tsao, Guadalupe
    SEMINARS IN LIVER DISEASE, 2008, 28 (01) : 26 - 42
  • [26] Nitric oxide in patients with cirrhosis and bacterial infections
    Such, JE
    Francés, R
    Pérez-Mateo, M
    METABOLIC BRAIN DISEASE, 2002, 17 (04) : 303 - 309
  • [27] Nitric Oxide in Patients with Cirrhosis and Bacterial Infections
    José Such
    Rubén Francés
    Miguel Pérez-Mateo
    Metabolic Brain Disease, 2002, 17 : 303 - 309
  • [28] Bacterial infections in alcoholic and nonalcoholic liver cirrhosis
    Sargenti, Konstantina
    Prytz, Hanne
    Nilsson, Emma
    Bertilsson, Sara
    Kalaitzakis, Evangelos
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 27 (09) : 1080 - 1086
  • [29] Risk factors and outcome of bacterial infections in cirrhosis
    Tony Bruns
    Henning W Zimmermann
    Andreas Stallmach
    World Journal of Gastroenterology, 2014, (10) : 2542 - 2554
  • [30] Changes in the epidemiology and management of bacterial infections in cirrhosis
    Piano, Salvatore
    Tonon, Marta
    Angeli, Paolo
    CLINICAL AND MOLECULAR HEPATOLOGY, 2021, 27 (03) : 437 - 445